Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME

 
• By Alaric DeArment
  
Eye
Oxurion announced that the Phase II study of THR-687 showed insufficient efficacy on its key endpoints • Source: Shutterstock

More from Strategy

More from Business